The potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.
The screening model combines maternal history, ultrasound data and several tests for blood markers to enable personalised treatment.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
Researchers discovered that measuring the concentrations of IL-18 in an individual’s blood could estimate future risk of stroke.
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
9 April 2024 | By Eurofins Discovery
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate.
The discovery of two proteins that effectively mature hiPSCs into endothelial cells may have a range of research and clinical benefits.